Aisling Capital, a late-stage life sciences investment firm that partners with companies to successfully bring novel medical therapies to market, today announced the closing of its newest fund, with $280 million in committed capital. The capital raised will allow Aisling Capital to continue helping clinical stage ventures improve global health by more rapidly bringing breakthrough medical treatments to market.
Aisling Capital will assist companies developing therapeutics to complete their clinical studies, navigate approval and ultimately reach commercialization. Portfolio companies gain access to Aisling Capital's strategic counsel and deep experience in both financial and medical fields, along with its unmatched network that extends from regulatory organizations to leading pharmaceutical companies and financial institutions. Aisling Capital is determined to increase the number of quality medical therapeutics in development and get treatments into the hands of people who need it.
"Today, every biotech company must develop treatments that generate significant upside for patient care through profound impact on disease, fewer side effects, and a shift away from toxic therapies toward a personalized approach," said Steve Elms, managing partner, Aisling Capital. "We are pleased to have the resources to continue to be a significant participant in our market and help the companies we invest in achieve this goal."
"We're extremely excited about the fund's potential and remain dedicated to increasing the number of quality medical treatments in development across a broad range of therapeutic areas including oncology, aesthetic dermatology and women's health," said Andrew Schiff, M.D., managing partner, Aisling Capital. "Over the last 17 years, we've helped bring to market some amazing medical innovations and look forward to getting these new treatments into the hands of people who need them as quickly and efficiently as possible."
Aisling Capital leverages the firm's partners' decades of capital markets and clinical experience to develop and bring to market breakthrough therapeutics that improve and save lives. The team is led by Managing Partners Steve Elms and Andrew Schiff, M.D.
About Aisling Capital
Aisling Capital is a late-stage life sciences investment partnership that leverages nearly 20 years of capital markets and clinical experience to invest in the development of breakthrough therapeutics that improve and save lives. Aisling Capital is a registered investment advisor with the U.S. Securities and Exchange Commission. For more information, please visit www.aislingcapital.com.